PubMed:24224997 / 3012-3247 JSONTXT

Annnotations TAB JSON ListView MergeView

    PubMed_Structured_Abstracts

    {"project":"PubMed_Structured_Abstracts","denotations":[{"id":"T4","span":{"begin":0,"end":235},"obj":"CONCLUSIONS"}],"text":"TARGIT concurrent with lumpectomy within a risk-adapted approach should be considered as an option for eligible patients with breast cancer carefully selected as per the TARGIT-A trial protocol, as an alternative to postoperative EBRT."}

    luoyt2021_800_3

    {"project":"luoyt2021_800_3","denotations":[{"id":"T2","span":{"begin":126,"end":139},"obj":"DP"}],"text":"TARGIT concurrent with lumpectomy within a risk-adapted approach should be considered as an option for eligible patients with breast cancer carefully selected as per the TARGIT-A trial protocol, as an alternative to postoperative EBRT."}

    Linmchun_800_3

    {"project":"Linmchun_800_3","denotations":[{"id":"T4","span":{"begin":126,"end":139},"obj":"DP"}],"text":"TARGIT concurrent with lumpectomy within a risk-adapted approach should be considered as an option for eligible patients with breast cancer carefully selected as per the TARGIT-A trial protocol, as an alternative to postoperative EBRT."}